Literature DB >> 15771707

The accuracy of meningioma grading: a 10-year retrospective audit.

J Willis1, C Smith, J W Ironside, S Erridge, I R Whittle, D Everington.   

Abstract

Although descriptive classifications of meningioma subtypes are well established, there has been inconsistency in the categorization of meningiomas into benign, atypical and anaplastic groups. The aim of this study was to reassess the incidence of atypical (grade II) meningiomas over a 10-year period by applying the World Health Organization (WHO) 2000 classification system. A secondary aim was to determine if grade II and III tumours were becoming more common. Sections of 314 meningiomas resected between 1994 and 2003 were retrieved from the archives of the Western General Hospital's neuropathology unit in Edinburgh. They were reassessed and graded by using the WHO 2000 classification system. The reviewers were blind to the original classification and grading. There was a gradual increase in the numbers of meningiomas being resected annually over the 10-year period. On reclassification, 78% of the meningiomas were classified as grade I, 20.4% as grade II and 1.6% as grade III. With regard to grade II meningiomas classified by using the WHO 2000 classification system, 38.1% had originally been classified as grade I prior to 2000, whereas 13.6% had originally been classified as grade I after 2000. In most cases, reclassification was due to formal counts of mitotic figures. Atypical meningiomas are diagnosed more frequently under the current WHO classification system than they were under the previous classification systems. Although the current WHO (2000) classification is more prescriptive than its predecessors, interobserver variability is likely to remain because of the subjective nature of some of the criteria.

Entities:  

Mesh:

Year:  2005        PMID: 15771707     DOI: 10.1111/j.1365-2990.2004.00621.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  56 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 2.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

3.  Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma.

Authors:  Shengjun Wang; Weidong Yang; Jinglan Deng; Jianning Zhang; Fucheng Ma; Jing Wang
Journal:  J Neurooncol       Date:  2013-05-09       Impact factor: 4.130

Review 4.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

5.  WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.

Authors:  Anne Ressel; Susanne Fichte; Michael Brodhun; Steffen K Rosahl; Ruediger Gerlach
Journal:  J Neurooncol       Date:  2019-10-01       Impact factor: 4.130

6.  Diffusion Profiling via a Histogram Approach Distinguishes Low-grade from High-grade Meningiomas, Can Reflect the Respective Proliferative Potential and Progesterone Receptor Status.

Authors:  Georg Alexander Gihr; Diana Horvath-Rizea; Nikita Garnov; Patricia Kohlhof-Meinecke; Oliver Ganslandt; Hans Henkes; Hans Jonas Meyer; Karl-Titus Hoffmann; Alexey Surov; Stefan Schob
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

7.  Extent of resection and survival outcomes in World Health Organization grade II meningiomas.

Authors:  Pranay Soni; Mark A Davison; Jianning Shao; Arbaz Momin; Diana Lopez; Lilyana Angelov; Gene H Barnett; Joung H Lee; Alireza M Mohammadi; Varun R Kshettry; Pablo F Recinos
Journal:  J Neurooncol       Date:  2020-11-17       Impact factor: 4.130

8.  Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.

Authors:  C Leland Rogers; Arie Perry; Stephanie Pugh; Michael A Vogelbaum; David Brachman; William McMillan; Joseph Jenrette; Igor Barani; Dennis Shrieve; Andy Sloan; Joseph Bovi; Young Kwok; Stuart H Burri; Samuel T Chao; Aaron C Spalding; Mitchell S Anscher; Beatrice Bloom; Minesh Mehta
Journal:  Neuro Oncol       Date:  2015-10-22       Impact factor: 12.300

9.  Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging.

Authors:  C-H Toh; M Castillo; A M-C Wong; K-C Wei; H-F Wong; S-H Ng; Y-L Wan
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

10.  Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity.

Authors:  Brian M Andersen; G Elizabeth Pluhar; Charles E Seiler; Michelle R Goulart; Karen S SantaCruz; Melissa M Schutten; Joyce P Meints; M Gerard O'Sullivan; R Timothy Bentley; Rebecca A Packer; Stephanie A Thomovsky; Annie V Chen; Dominik Faissler; Wei Chen; Matthew A Hunt; Michael R Olin; John R Ohlfest
Journal:  Cancer Res       Date:  2013-03-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.